A complete application in a minute — tailored resume and cover letter, ready to send.
Abiologics, Inc. in Watertown, MA, seeks a Senior Research Associate to join the Pharmacology team. You will perform hands-on rodent in vivo studies and coordinate work with contract labs to advance our Synteins program.
The role includes in vitro/ex vivo assays, molecular and cell biology work, data documentation, and cross-functional collaboration to support lead optimization and platform progression. Candidates should have a biology degree with 5–7 years (or MS with 3–5), experience in dosing
Watertown, MA
Company Description: Abiologics, Inc. is a privately held, early-stage biotechnology company on a mission to make biology better through an innovative therapeutic modality. We are pioneering the development of Synteins TM , a transformational class of macromolecular medicines unlocked by novel synthetic and computational technologies. Abiologics is actively seeking exceptional scientists who are passionate about driving therapeutic modality innovation in biotechnology.
Abiologics was founded in Flagship Pioneering’s venture creation engine, where companies such as Moderna Therapeutics (NASDAQ: MRNA) and Generate Biomedicines were conceived and created. Since Flagship’s founding in 2000, the firm has originated and fostered the development of more than 100 scientific ventures resulting in more than 500 issued patents and more than 50 clinical trials for novel therapeutic agents.
The Role: We are looking for a highly motivated, broadly skilled Senior Research Associate to join our growing Pharmacology team. In this role, the successful candidate will be responsible for hands‑on execution of rodent in vivo studies as well as coordination of studies with contract labs to support the progression of Abiologics’ pipeline. The incumbent may also contribute to in vitro and ex‑vivo pharmacology activities to progress projects and the platform, including molecular and cell biology assays and histology. This role will collaborate cross‑functionally with a diverse design‑make‑test team across Abiologics and have the opportunity to impact platform and company growth.
Flagship Pioneering invents and builds platform companies, each with the potential for multiple products that transform human health, sustainability and beyond. Since its launch in 2000, Flagship has originated more than 100 companies. Many of these companies have addressed humanity’s most urgent challenges: vaccinating billions of people against COVID-19, curing intractable diseases, improving human health, preempting illness, and feeding the world by improving the resiliency and sustainability of agriculture.
Flagship has been recognized twice on FORTUNE’s “Change the World” list, an annual ranking of companies that have made a positive social and environmental impact through activities that are part of their core business strategies and has been twice named to Fast Company’s annual list of the World’s Most Innovative Companies. Learn more about Flagship at www.flagshippioneering.com .
At Flagship, we accept impossible missions to enable bigger leaps. Our core values guide us through uncertainty and toward lasting impact.
We are an equal opportunity employer. All qualified applicants will be considered for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, protected veteran status, or any other characteristic protected by law.
We recognize that great candidates often bring unique strengthswithout fulfilling every qualification. If you have some of the experience listed above but not all, please apply anyway. We are dedicated to building diverse and inclusive teams and look forward to learning more about your backgroundand interest in Flagship.
The salary range for this role is $81,000 - $107,250. Compensation for the role will depend on a number of factors, including a candidate’s qualifications, skills, competencies, and experience. Abiologics, Inc currently offers
Compensation and benefits information is based on Abiologics, Inc's good faith estimate as of the date of publication and may be modified in the future.